COMPASS Pathways (CMPS) Competitors $6.60 +0.36 (+5.77%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$6.55 -0.05 (-0.74%) As of 10/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPS vs. IDYA, IRON, RXRX, BHC, IBRX, AGIO, ARQT, TVTX, SRPT, and DNLIShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), Arcutis Biotherapeutics (ARQT), Travere Therapeutics (TVTX), Sarepta Therapeutics (SRPT), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Its Competitors IDEAYA Biosciences Disc Medicine Recursion Pharmaceuticals Bausch Health Cos ImmunityBio Agios Pharmaceuticals Arcutis Biotherapeutics Travere Therapeutics Sarepta Therapeutics Denali Therapeutics IDEAYA Biosciences (NASDAQ:IDYA) and COMPASS Pathways (NASDAQ:CMPS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability. Do insiders & institutionals believe in IDYA or CMPS? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 2.5% of IDEAYA Biosciences shares are held by insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, IDYA or CMPS? IDEAYA Biosciences has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Does the media refer more to IDYA or CMPS? In the previous week, IDEAYA Biosciences had 2 more articles in the media than COMPASS Pathways. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 2 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 0.84 beat IDEAYA Biosciences' score of 0.39 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral COMPASS Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, IDYA or CMPS? COMPASS Pathways has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M336.04-$274.48M-$3.79-7.08COMPASS PathwaysN/AN/A-$155.12M-$1.84-3.59 Is IDYA or CMPS more profitable? IDEAYA Biosciences' return on equity of -31.42% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -31.42% -29.45% COMPASS Pathways N/A -87.89%-57.77% Do analysts recommend IDYA or CMPS? IDEAYA Biosciences presently has a consensus target price of $43.36, suggesting a potential upside of 61.54%. COMPASS Pathways has a consensus target price of $16.29, suggesting a potential upside of 146.75%. Given COMPASS Pathways' higher probable upside, analysts clearly believe COMPASS Pathways is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 1 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.72COMPASS Pathways 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 SummaryIDEAYA Biosciences and COMPASS Pathways tied by winning 7 of the 14 factors compared between the two stocks. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$598.67M$8.17B$6.10B$10.55BDividend YieldN/A2.83%5.69%4.75%P/E Ratio-3.5974.0085.4727.60Price / SalesN/A33.37582.22224.03Price / CashN/A22.8037.9261.55Price / Book2.926.9713.136.76Net Income-$155.12M$247.60M$3.30B$275.88M7 Day Performance9.82%1.11%4.29%2.81%1 Month Performance27.66%0.75%9.45%9.24%1 Year Performance9.45%13.32%86.64%35.42% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways3.164 of 5 stars$6.60+5.8%$16.29+146.8%+9.5%$598.67MN/A-3.59120Analyst ForecastIDYAIDEAYA Biosciences4.155 of 5 stars$27.49-0.5%$43.36+57.7%-13.6%$2.41B$7M-7.2580Positive NewsAnalyst ForecastIRONDisc Medicine2.3656 of 5 stars$69.28+2.2%$98.30+41.9%+46.7%$2.41BN/A-15.5030Analyst ForecastRXRXRecursion Pharmaceuticals1.8391 of 5 stars$5.53+0.7%$7.25+31.1%-5.4%$2.40B$58.84M-3.11400News CoverageAnalyst ForecastOptions VolumeBHCBausch Health Cos4.7567 of 5 stars$6.48-3.0%$9.00+38.9%-21.1%$2.40B$9.63B24.9220,700Positive NewsAnalyst ForecastIBRXImmunityBio2.6429 of 5 stars$2.53-0.4%$10.75+324.9%-28.1%$2.39B$14.74M-5.27590AGIOAgios Pharmaceuticals4.5192 of 5 stars$40.89+1.0%$56.00+37.0%+5.2%$2.38B$40.88M3.72390Analyst DowngradeARQTArcutis Biotherapeutics1.3742 of 5 stars$19.76-0.8%$19.80+0.2%+119.4%$2.37B$196.54M-26.35150TVTXTravere Therapeutics2.3489 of 5 stars$26.13+6.0%$34.20+30.9%+72.3%$2.33B$233.18M-12.81460Analyst ForecastSRPTSarepta Therapeutics4.5796 of 5 stars$23.26+2.7%$39.32+69.0%-80.5%$2.27B$2.48B-26.741,372Analyst ForecastDNLIDenali Therapeutics4.2875 of 5 stars$15.22-1.3%$33.50+120.1%-41.5%$2.23B$330.53M-5.44430Analyst Forecast Related Companies and Tools Related Companies IDYA Competitors IRON Competitors RXRX Competitors BHC Competitors IBRX Competitors AGIO Competitors ARQT Competitors TVTX Competitors SRPT Competitors DNLI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPS) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
